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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of different body weight management approaches in breast cancer survivors who are overweight or obese.
B A C K G R O U N D
Description of the condition
Breast cancer is the second most common cancer worldwide, with
1.67 million new cases diagnosed in 2012 (Ferlay 2015). With
early diagnosis and an increase in the use of neoadjuvant and ad-
juvant chemotherapy and hormonal therapy, survival rates have
continued to improve (IARC of WHO 2012). The five-year sur-
vival rate for breast cancer is now 89% in North America (NCI
2014), and over 80% in England (Office for National Statistics
2013). In light of the rapid increase in the number of breast can-
cer survivors, there is a new emphasis on the need for appropriate
survivorship care (Yu 2014).
In its broadest definition, a person becomes a cancer survivor when
they are diagnosed with cancer, and remain a survivor for the rest
of their life (Centers for Disease Control and Prevention 2011).
Approximately 50% of breast cancer survivors worldwide are clas-
sified as overweight or obese (57% to 62% in the United States
of America (Morimoto 2002; Imayama 2013), 55% in Switzer-
land (Eichholzer 2012) and 42% in Mexico (Ortiz-Mendoza
2014)). Many breast cancer survivors gain more body weight after
primary neoadjuvant or adjuvant treatment (Arce-Salinas 2014;
Kann 2014; Kim 2013) and hormonal therapy (Lorizio 2012).
Being overweight or obese is defined as having an abnormal or
excessive amount of total body fat, that may affect health status
(WHO 2015). It is usually measured by Body Mass Index (BMI
(kg/m2)), with overweight BMI classified as ranging from 25 to
29.9, obesity as a BMI of 30 and above, and morbid obesity as a
BMI of 40 and above (WHO 1997).
Body fat is composed mostly of adipocytes and other cells includ-
ing preadipocytes, fibroblasts, vascular endothelial cells and a va-
riety of immune cells. It can store energy, and cushion and insu-
late the body. It has been recognised as a major endocrine organ
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(Ferlay 2015; Kershaw 2004) as it produces hormones such as
leptin, oestrogen, and the cytokine tumour necrosis factor - alpha
(TNFα), which stimulates insulin secretion leading to insulin re-
sistance (Rock 2013; Su 2013). Research has demonstrated that
breast cancer survivors who have had a weight loss of 5% of
their initial weight have higher levels of oestrogen and leptin, and
lower levels of adiponectin than those who achieved a weight loss
of ≥5% of their initial weight (Rock 2013).
Studies suggest that women who are overweight or obese are at an
increased risk of cancer recurrence, and higher all-cause mortality
(Dignam 2003).Obesity has been found to increase the risk of total
mortality by 17%, and 18% for breast cancer specific mortality,
for every 5 kg/m2 increment before their cancer diagnosis (Chan
2014). In addition, morbid obesity may be a prognostic factor for
diabetes and cardiovascular disease (Vance 2011). Obesity also has
a significant impact on a woman’s quality of life (QOL) and ability
to function in relation to everyday activities (Imayama 2013).
Description of the intervention
A number of interventions have been adopted into clinical prac-
tice for breast cancer survivors who are morbidly obese, to re-
duce body weight and maintain it within a healthy weight range
(BMI of 18.5 to 24.9 kg/m2). These include: physical activity pro-
grammes (Thomas 2013), dietary changes (Pierce 2009), medi-
cation (Goodwin 2011) and bariatric surgery (Wikipedia 2015).
The weight loss approach selected needs to be matched to an in-
dividual patient’s needs, comorbidities, and risk profile. The most
common first-line strategy used for weight loss is comprehensive
lifestyle modification. The basic components are to facilitate en-
ergy deficiency through increased physical activity and reduced
calorie intake, generally with the goal of losing 3% to 5% of initial
body weight for at least six months.
Individually-tailored physical activity programmes generally con-
sist of a combination of aerobic resistance or weight load (strength
training) with aerobic exercises (such as walking, jogging, run-
ning, cycling, swimming, dancing etc). Recommendations are to
undertake at least 150 minutes per week of activity of moderate
intensity (Rock 2012; Subirats Bayego 2012; U.S. Department of
Health and Human Services 2008).
Weight loss diets have been designed to provide a balanced diet
with low energy intake of 1200 to 1500 kilocalories (kcal) per day
(d) for women and 1500 to 1800 kcal/d for men (Jensen 2014)
(or 1000 to 1600 kcal/d for a low calorie diet (Commonwealth
of Australia 2013)) for the management of overweight and obe-
sity in adults. This can be achieved through a low-fat, high-fibre
diet. A very-low-calorie diet (< 800 kcal/d) may be appropriate if
supervised in a medical setting. Behavioural, psychological and/
or social interventions are often used in conjunction with exercise
and dietary interventions.
Physical activity and weight loss dietary programmes are usually
administered in medical clinics, at home or in gyms. They can be
conducted face to face, by telephone or through web sites (Rogers
2008).
Pharmacotherapy can be used either as an adjunct to comprehen-
sive lifestyle modification, or in isolation for cancer survivors who
cannot participate in lifestyle programmes due, for example, to
comorbidities limiting their physical activity. Medications such as
sibutramine and orlistat are most commonly used to achieve or
maintain weight reduction in those with a BMI of 30 or above,
or BMI of 27 or above in the presence of obesity related co-
morbidities (e.g. diabetes, cardiovascular diseases) (Jensen 2014).
Sibutramine has been associated with an increased risk of elevated
blood pressure and tachycardia (fast heart rate) while orlistat can
lead to gastrointestinal side effects, deficiency of fat-soluble vita-
mins (e.g. vitamins A, D, E and K), and interactions with other
medications, e.g. warfarin (National Health andMedical Research
Council 2013).
Bariatric surgery may be considered for individuals with a BMI of
at least 40, or a BMI of 35 or above with high-risk comorbidities
(Jensen 2014) who have not responded to behavioural treatments,
with or without pharmacotherapy. Bariatric surgery includes a
variety of procedures where the aim is to achieve weight loss by
reducing the size of the stomach using a gastric band, or removing
a portion of the stomach (sleeve gastrectomy or biliopancreatic
diversionwith duodenal switch), or by resecting and re-routing the
small stomach pouch (gastric bypass surgery) to the small intestine.
Bariatric surgical interventions should be performed only in highly
selected patients and in specialist centres by experienced surgeons.
Patients need to be fully informed about the potential risks and
side effects. Adverse effects include misplacement of the band,
erosion of the gastric wall, port complications, anastomotic leak,
wound complications, haemorrhage, pulmonary embolism, deep
vein thrombosis, deficiency of nutrients or malnutrition, elevated
parathyroid hormone, ventral hernia and, occasionally, death (
Jensen 2014).
In this Cochrane review, we will include randomised controlled
clinical trials (RCTs), in which the participants are randomly al-
located to one or other of the different treatments under study.
We will evaluate several types of comparator interventions such
as placebo medications and supportive treatments (e.g. vitamins),
as well as evidence-based positive controlled interventions (e.g.
increased physical activity and diet modification regimens) (Pakiz
2011).
How the intervention might work
Obesity after a breast cancer diagnosis is known to be a poor
prognostic risk factor, particularly for postmenopausal women
(Chan 2014). This may be due to changes in energy metabolism
secondary to the side effects of chemotherapy treatment (Gadea
2013). There is likely to be higher than normal oestrogen conver-
sion and secretion in excess body fat tissue and less sex hormone
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binding globulin in the circulation (Siiteri 1987), which will in-
crease stimulation to breast tissue. Elevation of inflammatory cy-
tokines such as TNF-α, interleukin-6 (IL-6) and adipokines (lep-
tin) (Khandekar 2011) in adipose tissue can activate cancer cells
by activating oncogenic transcription in breast tissue, and a fall in
adiponectin decreases the inhibition of proliferation and metasta-
sis of breast tumour cells. Finally, high insulin levels and insulin
resistance (Oh 2011) may exacerbate the loco-regional metabolic
microenvironment leading to an imbalance in homeostasis, with
a depletion of oxygen, and energy dysfunction in localised breast
lesions, which are considered to be an ideal microenvironment for
tumour recurrence.
Under normal circumstances, obesity occurs when energy expen-
diture is less than the energy intake over a period of time (Davoodi
2013). However morbidly obese breast cancer survivors are often
characterised by fat gain and loss of lean tissue (Vance 2011). The
loss of muscle mass in the setting of increased body fat is known
as sarcopenic obesity. This is a multifactorial condition. In addi-
tion to the metabolic and neuroendocrine alterations that may be
induced by chemotherapy and genetics, other lifestyle-dependent
factors such as inactivity are likely to be important risk determi-
nants (Davoodi 2013). Other causes such as psycho-social and
environmental factors may also play a role in the excess accumula-
tion of adipose tissue (Deusinger 2012; Mastorakos 2010; Nahas
2012; Waxler-Morrison 1991).
There is a body of evidence finding that physical activity pro-
motes blood circulation and oxygen concentration, and reduces
the concentration of plasma cytokines and inflammatory factors
(nuclear factor kappaB (NF-κB), IL-6, C-reactive protein (CRP)),
insulin-like growth factor (IGF; Imayama 2013; Jones 2013), lep-
tin (Iantorno 2014), and hormones (insulin and oestrogens; Borer
2014; Rock 2004). Exercise can also improve body composition
(Guinan 2013). Studies of dietary modification suggest that exer-
cise has positive effects on loss of excess body weight and weight
loss maintenance for breast cancer survivors (Carpenter 2012;
Reeves 2014). These changes may be helpful in improving the
local breast microenvironment. In addition, management of body
weight may have preventative effects on secondary events associ-
ated with breast cancer such as type 2 diabetes, cardiovascular dis-
ease, dyslipidaemia and other comorbidities (Jensen 2014; Patnaik
2011). Loss of body weight can also have a positive impact on psy-
chosocial well being (Demark-Wahnefried 2012; Dignam 2003;
Imayama 2013).
Although over the counter medications for obesity in the non-
cancer population may reduce excess body weight by decreas-
ing macronutrient absorption (orlistat) and suppressing appetite
(sibutramine) (National Health and Medical Research Council
2013), and bariatric techniques through limiting food intake or
diminishing the area available for digestion and absorption in the
gastrointestinal tract (Bordalo 2011), there is a lack of evidence
for use of these methods in breast cancer survivors.
Why it is important to do this review
Changes in bodyweight associatedwith cancer treatment (Vagenas
2015) have been noted for a number of decades (Dixon 1978).
Studies indicate that body weight changes can occur in either di-
rection, with weight gain or loss (Vagenas 2015). This hetero-
geneity maybe associated with complex factors in breast cancer
survivors including: genetic predisposition (Slattery 2015), socio-
demographic factors (Sedjo 2014; Thompson 2014), menopausal
status (Irwin 2007), hormone receptor status (Ewertz 2012), clin-
ical presentation (tumour size, histologic grade and degree of dif-
ferentiation, lymph node metastasis) and treatment modality.
Cancer survivors gain weight mainly through sedentary and in-
active lifestyles, with a peak in the third year when followed for
six years after diagnosis (Makari-Judson 2014; Vagenas 2015).
Studies suggest that body weight loss of more than 5% is feasible
for obese or overweight breast cancer survivors (Davoodi 2013;
Vitolins 2014). However, many studies have been observational
in design (Makari-Judson 2014), with a paucity of high-quality
evidence from clinical interventions to guide effective body weight
management for cancer survivors. Consequently, body weight re-
duction is frequently not addressed in overweight breast cancer
survivors (Chan 2014). There is a need to elucidate its effective-
ness in terms of which modality to recommend, at what inten-
sity, and for which group of participants. In this review, we aim
to assess the benefits, risks and efficacy of different body weight
loss approaches in overweight breast cancer survivors in order to
guide the survivors, clinicians, and policy makers associated with
survivorship care.
O B J E C T I V E S
To assess the effects of different body weight management ap-
proaches in breast cancer survivors who are overweight or obese.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs), quasi-RCTs
and randomised cross-over trials evaluating management of body
weight for overweight and obese breast cancer survivors. There
will be no restrictions based on the language of the publication.
If studies are published in other languages, they will be translated
into English.
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Types of participants
We will include overweight or obese breast cancer survivors who
have been diagnosed with early stage breast cancer (histopatho-
logically confirmed), and who have no evidence of a recurrence of
their cancer. Participants who have had surgery and/or are receiv-
ing or have received adjuvant chemotherapy and/or radiotherapy,
adjuvant hormonal treatment and/or targeted therapies such as
trastuzumab for women with Her 2 status will be eligible. There
will be no restrictions based on participants’ residence, race or
ethnicity, occupation, gender, religion, education, socio-economic
status (SES), or time from diagnosis.
Types of interventions
The experimental interventions can involve:
• Physical activity that includes exercise as well as other
activities involving body movements that are done as part of
playing, working, active transportation, household chores and
recreational activities (WHO 1997). This may include physical
activity programmes alone, or in combination with various other
treatments. There are no limitations on the setting, duration and
delivery of the physical activity programme, but the aim of the
intervention needs to be weight loss.
• Dietary interventions that adhere to a foundation diet, with
the goal of losing 3% to 5% of body weight, and/or sustaining
weight loss for six months (Jensen 2014). Categories include a
low-calorie diet (< 1200 kcal/d) and very-low-calorie diet (< 800
kcal/d), based on participants’ needs and risk factors. There are
no restrictions on dietary type.
• Drugs that are aimed primarily at reducing obesity such as:
orlistat; sibutramine; L-carnitine, or other drugs such as
metformin used for secondary event prevention.
• Social, psychological, and behavioral interventions that are
aimed at improving the social environment, and cognitive and
behavioural factors in relation to weight loss.
• Bariatric surgery, which may include a variety of surgical
procedures including gastric banding, removal of a portion of the
stomach, or gastric bypass surgery.
• Multifactorial interventions could include a combination of
the following regimens: physical activity ± diet intervention ±
obesity drug ± bariatric surgery ± social, psychological, and
behavioural interventions.
The control interventions of comparisons will include: placebo,
no treatment or waiting list, supportive treatments such as vita-
mins and/or minerals, conventional treatments or active control
interventions to prevent the recurrence of cancer.
We will group the comparisons by interventions and controls in
the pooling.
We will include studies with co-interventions if these co-interven-
tions are applied in exactly the same way to both the control and
intervention group.
Types of outcome measures
Primary outcomes
1. Overall breast cancer survival, defined as the percentage of
breast cancer patients in a treatment group who are alive when
the precise cause of death is not specified.
2. Incidence of cancer recurrence after diagnosis: defined as
recurrence of any type of breast cancer in any region, after
completing definitive surgery for the incident breast cancer.
Secondary outcomes
1. Body weight loss (% of baseline weight), and weight loss
period (duration in days) for how long it took to lose the weight,
and how long the weight loss was sustained.
2. Change in skinfold thickness and waist circumference.
3. Disease-free survival rate, defined as the interval from
diagnosis to the date of first cancer recurrence.
4. Mortality (or crude death rate), defined as the total annual
number of any death recorded relative to the total population of
overweight and obese breast cancer survivors (usually expressed
per 1000) between completing definitive surgery and the end of
the data linkage. This will be categorised into breast cancer
deaths and non-breast cancer deaths of breast cancer survivors.
5. Any potential adverse events such as exacerbation of
symptoms (pain, fatigue, nausea, dyspnoea), falls and bone
fractures.
6. Quality of life (QOL) and patient-reported outcomes, as
defined by the perceived quality of an individual’s daily life; that
is, an assessment of their well being or lack thereof. This includes
all emotional, social, and physical aspects of the individual’s life.
The patient-reported outcomes may be assessed using
questionnaires or surveys used to collect data from the patient,
such as the EORTC QLQ-C30 , FACT-G or SF-36
questionnaires. We will include data from self-administered
structured questionnaires including participants’ self-reported
socio-demographic (race/ethnicity) and medical characteristics
(lump before mammogram, menopausal status) and QOL.
7. Concentration of oestradiol, androgen, insulin, insulin-like
growth factor (IGF), fasting glucose and lipids profile.
8. Adipokine levels concentrations (µg/mL): plasma leptin,
adiponectin.
9. Inflammatatory marker concentrations (pg/ml) (IL-6,
TNF-α, CRP).
Main outcomes for ’Summary of findings’ table
The following outcomes will be included in the ’Summary of
findings’ table(s).
1. Overall breast cancer survival.
2. Incidence of cancer recurrence after diagnosis.
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3. Any potential adverse events.
4. Body weight loss.
5. Disease-free survival rate.
6. Mortality.
7. Change in skinfold thickness and waist circumference.
Search methods for identification of studies
Electronic searches
We will search the following databases.
1. The Cochrane Breast Cancer Group’s (CBCG’s) Specialised
Register. Details of the search strategies used by the Group for
the identification of studies and the procedure used to code
references are outlined in the Group’s module (http://
www.mrw.interscience.wiley.com/cochrane/clabout/articles/
BREASTCA/frame.html). Trials with the key words ’breast
cancer survivor’, ’survivorship’, ’breast cancer’, ’obesity’,
’overweight’, ’body weight management’, ’weight loss’, ’weight
reduction’, ’body mass index’, ’lifestyle intervention’, ’lifestyle
activity’, ’exercise’, ’diet’, ’bariatric surgery’, ’obesity medication’,
’behavior’, ’drug therapy’ ’cognitive therapy’ and ’surgery’ will be
extracted and considered for inclusion in the review.
2. Cochrane Central Register of Controlled Trials
(CENTRAL, The Cochrane Library, latest issue). See Appendix
1.
3. MEDLINE (2012 to present) (via OvidSP). See Appendix
2.
4. EMBASE (2016 to present) (via EMBASE.com). See
Appendix 3.
5. The WHO International Clinical Trials Registry Platform
(ICTRP) search portal (http://apps.who.int/trialsearch/
Default.aspx) for all prospectively registered and ongoing trials.
See Appendix 4.
6. Clinicaltrials.gov (http://clinicaltrials.gov/). See Appendix
5.
7. Mainland Chinese academic literature databases using
keywords in Chinese: CNKI (via http://www.cnki.net/) (1979 to
present); VIP (http://edu.cqvip.com/) (1989 to present); Wan
Fang Data (http://www.wanfangdata.com.cn/) (1980 to present);
SinoMed (http://www.sinomed.ac.cn/zh/) (1978 to present).
Searching other resources
Bibliographic searching
We will attempt to identify further studies from reference lists of
identified relevant trials or reviews. A copy of the full article for
each reference reporting a potentially-eligible trial will be obtained.
Where this is not possible, we will attempt to contact authors to
obtain additional information.
We will handsearch the retrieved articles and bibliographies in
order to identify other potentially-eligible studies and unpublished
data.
Data collection and analysis
Selection of studies
Two authors (LXM and SYT) will independently screen the titles
and abstracts. LXM and SYT will obtain full-text copies of the
relevant articles and include the eligible studies in accordance with
the above inclusion criteria. During this process any disagreement
will be resolved by consensus and by the involvement of other
review authors (MKB and JV). We will record excluded trials in
the ’Characteristics of excluded studies’ table.
Data extraction and management
Data will be collected in accordance with the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011) based on the
inclusion criteria.
Data will be extracted from eligible studies using a data extrac-
tion form designed and pilot-tested by the authors. We will col-
lect the following information: study design, participants, setting,
interventions, outcomes, follow-up, and any other items relevant
to this review (see Appendix 6 for a list of the categories of data
collection). Where studies have multiple publications, the main
trial report will be used as the primary reference and additional de-
tails supplemented from all papers. Two authors (LXM and SYT)
will independently extract the data, and any uncertainties will be
discussed with other authors (MKB and JV). Review authors will
contact the study investigators if required.
Assessment of risk of bias in included studies
The risk of bias in the included studies will be assessed by two
authors (LXM and SYT) using Cochrane’s ’Risk of bias’ assess-
ment tool. Relevant items include: sequence generation; allocation
concealment; blinding of participants and providers; blinding of
outcome assessors; completeness of outcome data; selective out-
come reporting; and other potential sources of bias. Two authors
will assess these ’Risk of bias’ domains independently, with any
disagreements resolved by consensus or by discussion with other
authors (MKB and JV). All judgments will be fully described in
the ’Risk of bias’ table and classified as ’low risk’, ’high risk’, and
’unclear risk’. The results will be incorporated into the interpreta-
tion of review findings by means of a sensitivity analyses.
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Measures of treatment effect
Dichotomous outcomes, including the all cause mortality rate in
overweight and obese breast cancer survivors will be expressed
as risk ratios (RRs), and the adverse effects of the intervention
will be expressed as odds ratio (OR), along with 95% confidence
intervals (CIs). The number of events occurring in the control and
intervention groups for each study will be used to calculate the
outcomes.
Time-to-event outcomes including survival and local recurrence
will be expressed as hazard ratios (HRs). If they are available, the
observed number of events and expected number of events in
both the experimental and control group of each study will be
extracted directly from the trial publication. For data presented
in Kaplan-Meier curves, a Cox proportional hazard model or in
life tables, we will extract the HR and associated variances from
published curves using methods described by Parmar (Parmar
1998). Censored participants will not be analysed as dichotomous
variables.
Continuous data including body weight loss, skinfold thickness,
waist circumference, levels of hormones, cytokines and adipokines,
and metabolic effects will be expressed as the mean differences
(MDs) between treatment groups with 95% CIs, when all studies
report exactly the same outcomes. If similar outcomes are reported
on different scales (for example, change in QOL) the standardised
mean difference (SMD) will be calculated with 95% CIs.
When comparing the intervention benefits or risk effects, particu-
lar pooling outcomes will be displayed graphically as forest plots.
A survival rate ratio of greater than 1.0 will be considered a positive
response, favouring a body weight management regimen. The rate
of cancer recurrence or incidence of adverse effects (e.g. incidence
of fat soluble vitamin deficiencies) are detrimental responses, and
a rate of less than 1.0 will favour a body weight management reg-
imen.
Unit of analysis issues
Cross-over trial design will be eligible for inclusion, but only the
data collected from the first stage will be used in themeta-analysis.
For three-arm trials, we will combine groups to create a single pair-
wise comparison.
Dealing with missing data
In this review, missing data will be of significance as it is antici-
pated that many of the studies meeting the eligibility criteria for
inclusion may not report the desired study outcomes of the partic-
ipants. If the results of an RCT have been published but informa-
tion on the outcome of interest has not been reported, an attempt
will be made, whenever possible, to contact the trial authors for
the missing information. All efforts made to obtain additional in-
formation will be reported in the completed review. Where possi-
ble, all analyses will be by intention-to-treat. If participants were
allocated to one intervention, but after randomisation underwent
a different intervention, they will be analysed according to their
randomisation allocation. If the results for dichotomous variables
are not reported in some participants, we will analyse based on
both aworst possible outcome and a best possible outcome.Where
results are unobtainable, multiple imputation of individual val-
ues will be undertaken for the primary outcomes only (Ellington
2015). If a standard deviation (SD) is missing we will use the
method described by Hozo et al (Hozo 2015). A change in QOL
will be assumed not to have occurred in participants with unre-
ported outcomes. For other outcomes, only the available data will
be analysed.Wewill discuss the impact of missing data in the ’Dis-
cussion’ section of the review. Any imputation undertaken will be
subject to sensitivity analysis.
Assessment of heterogeneity
Clinical characteristics, such as breast cancer subtypes and treat-
ments, may not be randomly distributed across treatment and
control groups, and/or not be described or accounted for in many
studies. This may result in heterogeneity. In this review we will
consider whether these clinical and other methodological charac-
teristics of the included studies are sufficiently similar for meta-
analysis to provide ameaningful summary. Visual inspection of the
forest plots will be used to assess heterogeneity. In addition, a value
of the I2 statistic greater than 50% or the P value for Chi2 less than
0.1 will indicate substantial heterogeneity (Higgins 2011). When
there is consistency among the effect size of included studies, the
fixed-effect model will be applied to quantitatively synthesise the
evidence from the studies. If substantial heterogeneity is detected,
we will use a random-effects model to pool the results. Possible
explanations for the heterogeneity will be explored using subgroup
and sensitivity analyses.
Assessment of reporting biases
In view of the difficulty in detecting and correcting for publication
bias and other reporting biases, we will aim to minimise their
potential impact by ensuring a comprehensive search for eligible
studies and by being alert to duplication of data. If there are 10
or more studies for one effect outcome analysis, a funnel plot will
be prepared to explore the possibility of small study effects (that
is a tendency for the intervention effect to be more beneficial in
smaller studies).
Data synthesis
For dichotomous outcomes, wewill synthesise data using theMan-
tel-Haenszel analysis method for a fixed-effect model or the Der-
Simonian and Laird analysis method for a random-effects model.
The Peto method will be used to pool odds ratios.The choice of
model will be based on the assessment of heterogeneity.
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For time-to-event outcomes, we will pool data using the generic
inverse-variance method, allowing a mixture of log-rank and Cox
model estimates to be obtained from studies.
For continuous outcomes, MDs and their 95% CI (body weight
loss) or SMDs with 95% CI (for a QOL scale) will be calculated
based on intention-to-treat data, available-case data and per-pro-
tocol data. As we assume that intention-to-treat data for continu-
ous measures will not be available for a number of studies, we will
use a preference approach for collecting data for the primary meta-
analysis (first preference intention-to-treat data, second preference
available-case data, and third preference per-protocol data).
We will performmeta-analysis using ReviewManager 5.3 software
(RevMan) and report the meta-analysis results mainly by forest
plots and ’Summary of findings’ tables.
We will use GRADEproGDT software (GRADEproGDT) to
present a ’Summary of finding’ (SoF) table to illustrate the main
outcomes and grade the quality of the evidence.
We will grade the quality of the evidence for the two primary
outcomes and the five secondary outcomes listed above in terms
of the extent of our confidence in the estimates of effects. In the
SoF table, findings will be grouped by outcome. We will record a
summary of the estimated intervention effect, number of studies
and participants, and justification of the evidence for each out-
come. GRADE criteria for assessing the quality of the evidence
will include study limitations, inconsistency, imprecision, indi-
rectness, publication bias and other considerations (Schünemann
2011). Four grades of evidence will be used, as recommended by
the GRADE Working Group, as follows:
1. High quality: Further research is very unlikely to change
our confidence in the estimate of effect;
2. Moderate quality: Further research is likely to have an
important impact on our confidence in the estimate of effect and
may change the estimate;
3. Low quality: Further research is very likely to have an
important impact on our confidence in the estimate of effect and
is likely to change the estimate;
4. Very low quality: We are very uncertain about the estimate.
Two authors (CT and JV) will work on this assessment.
Subgroup analysis and investigation of heterogeneity
We will perform subgroup analyses to assess the heterogeneity of
studies as well as the effect on clinical outcomes. Where there is
heterogeneity we will explore its potential causes and discuss as-
pects of the study design, participant characteristics, interventions
and outcome types. Themain subgroup analyses will be as follows:
1. Hormonal receptor status (oestrogen, progesterone) and
triple negative status;
2. Different races or ethnicity;
3. Age: < 45 years versus > 45 years;
4. Menopausal status: premenopausal versus postmenopausal;
5. Different types of diets;
6. Stage and status of tumour at diagnosis;
7. Body weight before commencing the study programme;
8. Different types of control groups;
9. Treatment status: chemotherapy: none, completed,
ongoing; hormonal therapy: none, completed, ongoing; HER2-
directed therapy: none, completed, ongoing.
10. The time of the weight gain (weight gain as a result of
treatment versus obesity/overweight at the time of diagnosis).
Sensitivity analysis
Where data are available, sensitivity analyses will be performed to
determine whether the pooling of results is robust in terms of the
arbitrary decisions made regarding the eligibility of studies and the
methods of meta-analysis. Sensitivity analysis will be conducted
by excluding studies with a high risk of bias, by excluding un-
published studies or by using different pooling methods. We will
exclude studies of poor overall methodological quality, i.e. quasi-
randomisation, without adequate safeguards for allocation con-
cealment, inadequate blinding, incomplete outcome reports and
no intention-to-treat analysis, to determine the statistical stability
of the results. Where forest plots and I2 values suggest heterogene-
ity we will change from a fixed-effect model to a random-effects
model or exclude the most outlying results in the forest plot and
repeat the meta-analysis.
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A P P E N D I C E S
Appendix 1. CENTRAL
#1 MeSH descriptor: [Breast Neoplasms] explode all trees
#2 breast near neoplasm*
#3 breast near carcinom*
#4 breast near cancer*
#5 breast near tumour*
#6 breast near tumor*
#7 breast near malignan*
#8 #1 or #2 or #3 or #4 or #5 or #6 or #7
#9 MeSH descriptor: [Weight Reduction Programs] explode all trees
#10 weight reduction program* or weight near reduction near program*
#11 MeSH descriptor: [Weight Loss] explode all trees
#12 weight loss or weight near loss
#13 MeSH descriptor: [Body Weight Changes] explode all trees
#14 body weight chang* or body near weight near chang*
#15 MeSH descriptor: [Exercise] explode all trees
#16 MeSH descriptor: [Exercise Therapy] explode all trees
#17 exercis*
#18 exercise therap* or exercise near therap*
#19 MeSH descriptor: [Exercise Movement Techniques] explode all trees
#20 MeSH descriptor: [Physical Education and Training] explode all trees
#21 physical education and train*
#22 MeSH descriptor: [Physical Fitness] explode all trees
#23 physical near fitness or physical fitness
#24 MeSH descriptor: [Physical Exertion] explode all trees
#25 physical exertion or physical near exertion
#26 MeSH descriptor: [Sports] explode all trees
#27 sport*
#28 MeSH descriptor: [Motor Activity] explode all trees
#29 motor near activit* or physical activit* or physical near activit*
#30 MeSH descriptor: [Walking] explode all trees
#31 walk*
#32 MeSH descriptor: [Jogging] explode all trees
#33 jog*
#34 MeSH descriptor: [Swimming] explode all trees
#35 swim*
#36 MeSH descriptor: [Bicycling] explode all trees
#37 bicycl*
#38 MeSH descriptor: [Resistance Training] explode all trees
#39 (resistance or strength or weight) near train* or resistance train* or strength train* or weight train*
#40 MeSH descriptor: [Dancing] explode all trees
#41 MeSH descriptor: [Dance Therapy] explode all trees
#42 danc* near therap* or danc* therap* or danc*
#43 aerobic* near exercis* or aerobic exercis*
#44 MeSH descriptor: [Diet] explode all trees
#45 diet*
#46 MeSH descriptor: [Diet Therapy] explode all trees
#47 diet therapy or diet* near therap*
#48 MeSH descriptor: [Diet, Reducing] explode all trees
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#49 body weight management or body near weight near manag* or weight management or weight near manag*
#50 MeSH descriptor: [Bariatric Surgery] explode all trees
#51 bariatric surger* or bariatric near surger*
#52 MeSH descriptor: [Bariatrics] explode all trees
#53 bariatrics
#54 MeSH descriptor: [Anti-Obesity Agents] explode all trees
#55 anti-obesity agent* or anti-obesity near agent* or anti-obesity drug* or anti-obesity near drug* or anti-obesity medic* or anti-
obesity near medic*
#56 weight loss drug* or weight near loss near drug*
#57 weight loss medic* or weight near loss near medic*
#58 orlistat
#59 sibutramine
#60 L-carnitine or carnitine
#61 metformin
#62 weight loss intervention or weight near loss near intervention*
#63 MeSH descriptor: [Behavior Therapy] explode all trees
#64 behavior therap* or behavior near therap* or behaviour therap* or behaviour near therap*
#65 MeSH descriptor: [Cognitive Therapy] explode all trees
#66 cogniti* therap* or cogniti* near therap*
#67 MeSH descriptor: [Psychotherapy] explode all trees
#68 psychotherap*
#69 lifestyle modification or lifestyle near modif*
#70 #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or
#27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #
45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63
or #64 or #65 or #66 or #67 or #68 or #69
#71 #8 and #70
Appendix 2. MEDLINE (via OvidSP)
1 randomized controlled trial.pt.
2 controlled clinical trial.pt.
3 randomized.ab.
4 placebo.ab.
5 Clinical Trials as Topic/
6 randomly.ab.
7 trial.ti.
8 (crossover or cross-over).tw.
9 Pragmatic Clinical Trials as Topic/
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(Continued)
10 pragmatic clinical trial.pt.
11 or/1-10
12 exp Breast Neoplasms/
13 (breast adj6 cancer$).tw.
14 (breast adj6 neoplasm$).tw.
15 (breast adj6 carcinoma$).tw.
16 (breast adj6 tumo?r$).tw.
17 or/12-16
18 exp Weight Reduction Programs/
19 weight reduc* program*.tw.
20 exp Weight Loss/
21 weight loss.tw.
22 exp body weight changes/
23 exp Exercise/
24 exercise.tw.
25 exp Exercise Movement Techniques/
26 exp Exercise Therapy/
27 exercise therap*.tw.
28 exp “Physical Education and Training”/
29 ((physical adj6 education) and training).tw.
30 (physical and (education adj6 training)).tw.
31 ((physical adj6 education) and training).tw.
32 (physical and (education adj6 training)).tw.
33 exp Physical Fitness/
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34 physical fitness.tw.





















56 (dance adj6 therap*).tw.
57 dance therap*.tw.
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(Continued)




62 ((resistance or strength) and train*).tw.
63 ((resistance or strength) adj6 train*).tw.
64 strength train*.tw.
65 exp Diet Therapy/
66 exp Diet/




71 body weight management.tw.
72 (weight adj6 manag*).tw.
73 exp bariatric surgery/
74 bariatric surger*.tw.
75 (bariatric adj6 surger*).tw.
76 exp Bariatrics/
77 exp Anti-Obesity Agents/
78 anti-obesity drug*.tw.
79 (anti-obesity adj6 drug).tw.
80 exp Appetite Depressants/
81 (obesity adj6 (drug* or medic*)).tw.
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(Continued)
82 weight loss drug*.tw.
83 weight loss medic*.tw.
84 ((weight and loss) adj6 (drug* or medic*)).tw.





90 weight loss intervention.tw.
91 ((weight and loss) adj6 intervention*).tw.
92 ((weight adj6 loss) and intervention*).tw.
93 exp Behavior Therapy/
94 behaviour therap*.tw.
95 (behaviour adj6 therap*).tw.
96 exp Cognitive Therapy/
97 cogniti* therap*.tw.
98 (cogniti* adj6 therap*).tw.
99 exp Psychotherapy/
100 lifestyle modification.tw.
101 (lifestyle adj6 modif*).tw.
102 or/18-101
103 11 and 17 and 102
104 exp animals/ not humans/
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(Continued)
105 103 not 104
Appendix 3. EMBASE (via Embase.com)
#1 random* OR factorial* OR crossover* OR cross NEXT/1 over* OR placebo* OR (doubl* AND blind*) OR (singl* AND
blind*)OR assign*OR allocat*ORvolunteer*OR ’crossover procedure’/expOR ’double blind procedure’/expOR ’randomized
controlled trial’/exp OR ’single blind procedure’/exp
#2 ’breast’/exp OR ’breast disease’/exp AND ’neoplasm’/exp OR ’breast tumor’/exp OR (breast* NEAR/5 neoplas*):ab,ti OR
(breast* NEAR/5 cancer*):ab,ti OR (breast* NEAR/5 carcin*):ab,ti OR (breast* NEAR/5 tumo*):ab,ti OR (breast* NEAR/5
metasta*):ab,ti OR (breast* NEAR/5 malig*):ab,ti
#3 ’breast cancer’/exp OR ’breast cancer’ OR ’breast neoplasm’ OR ’breast carcinoma’/exp OR ’breast carcinoma’ OR ’breast
tumour’ OR ’breast tumor’/exp OR ’breast tumor’
#4 #2 OR #3
#5 ’weight reduction’/exp OR ’weight reduction’ OR ’weight reduction’ NEAR/6 program* OR ’weight loss’ NEAR/6 program*
#6 ’aerobic exercise’/exp OR ’aerobic exercise’ OR aerobic NEAR/6 exercise*
#7 ’exercise’/exp OR ’exercise’
#8 ’kinesiotherapy’/exp OR ’exercise therapy’ OR exercise* NEAR/6 therap*
#9 ’movement therapy’/deOR ’movement therapy’ORmovementNEAR/6 therap*OR ’exercisemovement’OR exercise*NEAR/
6 movement
#10 ’physical education’/exp OR ’physical education and training’ OR physical NEAR/6 education*
#11 ’fitness’/exp OR ’physical fitness’ OR physical NEAR/6 fitness
#12 ’physical exertion’OR physical NEAR/6 exertion
#13 ’sport’/exp OR ’sports’ OR sport*
#14 ’physical activity’/exp OR ’physical activity’ OR physical NEAR/6 activit*
#15 ’motor activity’/exp OR ’motor activity’ OR motor NEAR/6 activit*
#16 ’walking’/exp OR ’walking’ OR walk*
#17 ’jogging’/exp OR ’jogging’ OR jog*
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(Continued)
#18 ’swimming’/exp OR ’swimming’ OR swim*
#19 ’cycling’/exp OR ’cycling’ OR ’bicycling’ OR bicycl*
#20 ’weight lifting’/exp OR ’weight lifting’ OR weight NEAR/6 lift* OR ’weight training’ OR weight NEAR/6 train*
#21 ’dance therapy’/expOR ’dance therapy’ OR danc* NEAR/6 therap*OR ’dance movement therapy’ OR dance ANDmovement
AND therap*
#22 ’resistance training’/exp OR ’resistance training’ OR resistance NEAR/6 train* OR ’strength training’ OR strength NEAR/6
train*
#23 ’diet therapy’/exp OR ’diet therapy’ OR diet NEAR/6 therap*
#24 ’diet’/exp OR ’diet’
#25 ’body weight’/exp OR ’body weight’ OR bod* NEAR/6 weight*
#26 ’body weight management’ OR ’body weight’ NEAR/6 manag* OR weight* NEAR/6 manag*
#27 ’bariatric surgery’/exp OR ’bariatric surgery’ OR bariatric* NEAR/6 surger*
#28 ’bariatrics’/exp OR ’bariatrics’ OR bariatric*
#29 ’antiobesity agent’/exp OR ’anti-obesity agent’ OR ’anti obesity’ NEAR/6 agent* OR ’anti-obesity drug’ OR ’anti-obesity’
NEAR/6 drug* OR ’anti-obesity medication’ OR ’anti-obesity’ NEAR/6 medic*
#30 ’anorexigenic agent’/exp OR ’appetite suppressant’ OR appetite NEAR/6 suppressant
#31 ’weight loss medication’OR ’weight loss’ NEAR/6 (medic* OR drug*) OR ’weight loss drug’
#32 orlistat
#33 sibutramine
#34 ’carnitine’/exp OR ’carnitine’ OR ’l-carnitine’
#35 ’metformin’/exp OR ’metformin’
#36 ’weight loss intervention’OR ’weight loss’ NEAR/6 intervention
#37 ’behavior therapy’/expOR ’behavior therapy’ OR behavior* NEAR/6 therap* OR ’behaviour therapy’ OR behaviour* NEAR/
6 therap*
#38 ’cognitive therapy’/exp OR ’cognitive therapy’ OR cognit* NEAR/6 therap*
#39 ’psychotherapy’/exp OR ’psychotherapy’ OR psychotherap*
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(Continued)
#40 ’lifestyle modification’/exp OR ’lifestyle modification’ OR lifestyle* NEAR/6 modif*
#41 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19
OR #20 OR #21 OR #22 OR#23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33
OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40
#42 #1 AND #4 AND #41
#43 #42 AND [humans]/lim AND [embase]/lim
Appendix 4. WHO ICTRP search portal
Basic searches:
1. breast cancer AND weight loss
2. breast cancer AND exercise
3. breast cancer AND physical activity
4. breast cancer AND diet
5. breast cancer AND bariatric surgery
6. breast cancer AND anti-obesity drug
7. breast cancer AND lifestyle modification
8. breast cancer AND behavior modification
9. breast cancer AND behaviour modification
Advanced searches:
1. Title: Body weight management in breast cancer survivors
Recruitment status: ALL
2. Condition: breast cancer OR breast neoplasm
Intervention: weight loss OR weight reduction
Recruitment status: ALL
3. Condition: breast cancer OR breast neoplasm
Intervention: exercis* OR exercise therap* OR sport* OR physical activit* OR walk* OR jog* OR swim* OR bicycl* OR weight
training OR dancing OR dance OR resistance OR strength
Recruitment status: ALL
4. Condition: breast cancer OR breast neoplasm
Intervention: body weight management OR weight management OR diet OR diet therap* OR bariatric surger* OR weight loss surgery
Recruitment status: All
5. Condition: breast cancer OR breast neoplasm
Intervention: weight loss drug OR weight loss medic* OR anti-obesity drug OR anti-obesity medic* OR anti obesity agents OR orlistat
OR sibutramine OR L-carnitine OR carnitine OR metformin
Recruitment status: All
6. Condition: breast cancer OR breast neoplasm
Intervention: behavior therap* OR behaviour therap* OR cognitive therap* OR psychotherap* OR lifestyle modification
Recruitment status: All
20Body weight management in overweight and obese breast cancer survivors (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 5. Clinicaltrials.gov
Basic searches:
1. breast cancer AND weight loss
2. breast cancer AND exercise
3. breast cancer AND physical activity
4. breast cancer AND diet
5. breast cancer AND weight loss surgery
6. breast cancer AND anti obesity agents
7. breast cancer AND lifestyle modification
8. breast cancer AND behavior modification
Advanced searches:
1. Title: Body weight management in breast cancer survivors
Recruitment: All studies
Study Results: All studies
Study Type: All studies
2. Conditions: breast cancer OR breast neoplasm
Interventions: weight loss OR weight reduction
Recruitment status: All studies
Study type: All studies
3. Condition: breast cancer OR breast neoplasm
Intervention: exercis* OR exercise therap* OR sport* OR physical activit* OR walk* OR jog* OR swim* OR bicycl* OR weight
training OR dancing OR dance OR resistance OR strength
Recruitment status: All studies
Study Results: All studies
Study type: All studies
4. Condition: breast cancer OR breast neoplasm
Intervention: body weight management OR weight management OR diet OR diet therap* OR bariatric surger* OR weight loss surgery
Recruitment status: All studies
Study Results: All studies
Study type: All studies
5. Condition: breast cancer OR breast neoplasm
Intervention: weight loss drug OR weight loss medic* OR anti-obesity drug OR anti-obesity medic* OR anti obesity agents OR orlistat
OR sibutramine OR L-carnitine OR carnitine OR metformin
Recruitment status: All studies
Study Results: All studies
Study type: All studies
6. Condition: breast cancer OR breast neoplasm
Intervention: behavior therap*OR behaviour therap*OR cognitive therap*OR psychotherap*OR lifestylemodification* OR behavior
modification*
Recruitment status: All studies
Study Results: All studies
Study type: All studies
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Appendix 6. Data extraction table
Source: Study ID, review author ID, and citation and contact details (Correspondence).
For methods: study design, total study duration, sequence generation, allocation sequence concealment, blinding, and other concerns
about bias (see ’Risk of bias’ table).
For participants: Total numbers indicate whether excluded before or after Tx, and the numbers randomised, excluded, lost to follow-
up, changed Tx and evaluated; in addition, setting, diagnostic criteria, age, sex, country, co-morbidity, social-demographics, ethnicity
and date of study.
For interventions: total number of intervention groups, intervention details such as route, total dose or intensity, timing, duration,
supervision; drug source (sufficient for replication, if feasible).
For outcomes: outcomes and time points (collected and reported), outcome definition (with diagnostic criteria), unit of measurement,
for scales: upper and lower limits, and whether high or low score is good. For each outcome result: sample size, missing participants,
summary data for each intervention group (e.g. 2×2 table for dichotomous data; means and SDs for continuous data), Estimate of
effect with confidence interval and P value.
Investigator contacted for more information: Yes / No
If Yes, highlight on the form the information that was provided
C O N T R I B U T I O N S O F A U T H O R S
1. Draft of protocol: JV, LXM, MKB, and SYT
2. Study selection: LXM, SYT, JV and MKB
3. Extract data from studies: LXM, SYT, JV and MKB
4. Enter data into RevMan: LXM, SYT, JV and MKB
5. Carry out the analysis: LXM, SYT, JV and MKB
6. Interpret the analysis: JV, LXM, SYT and MKB
7. Draft the final review: JV, LXM, SYT and MKB
8. Disagreement resolution: JV and MKB
9. Update the review: JV, LXM, SYT and MKB
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